Annual Report And Financial Statements

Overview

The report describes significant 2025 progress across Genflow's human and animal health programmes, including advancement of MASH and sarcopenia work, initiation of the glaucoma programme and canine clinical trial, and a strategic transition from AAV to mRNA/LNP delivery. It also presents the Group's TCFD progress, Board oversight of climate-related matters, and commitments to energy efficiency, waste minimisation and environmental sustainability.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services